CTT Pharmaceutical Holdings (CTTH) Ratios
CTT Pharmaceutical Holdings Ratios
CTTH's free cash flow for Q2 2026 was $-7.06K. For the 2026 fiscal year, CTTH's free cash flow was increased by $0.00 and operating cash flow was $-7.06K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.50 | 0.00 | 0.00 | 1.76 | 1.05 |
| Quick Ratio | 0.50 | 0.00 | 0.00 | 1.76 | 1.05 |
| Cash Ratio | 0.50 | 0.00 | 0.00 | 1.75 | 1.00 |
| Solvency Ratio | -4.82 | -4.98 | -1.86 | -10.20 | 1.01 |
| Operating Cash Flow Ratio | -2.43 | -0.83 | -2.51 | -30.09 | -5.86 |
| Short-Term Operating Cash Flow Coverage | -4.01 | -2.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -15.66K | $ -40.74K | $ -19.29K | $ 3.53K | $ 5.28K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.23 | 0.14 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.34 | 0.53 | 0.18 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.25 | 0.34 | 0.15 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.56 | 2.27 | 1.32 | 1.05 | 20.41 |
| Debt Service Coverage Ratio | -5.78 | -12.85 | -295.01 | -19.13 | 0.00 |
| Interest Coverage Ratio | -63.26 | -122.37 | -347.85 | -46.64 | 0.00 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.03 | -0.07 | -0.30 | 0.18 | -0.99 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 122.98% | 84.00% | 100.30% | 49.03% | 89.86% |
| Return on Assets (ROA) | -180.95% | -287.51% | -53.22% | -56.94% | -123.49% |
| Return on Equity (ROE) | -282.65% | -652.52% | -70.32% | -59.89% | -2520.85% |
| Return on Capital Employed (ROCE) | -229.91% | -776.81% | -59.35% | -122.13% | -2805.16% |
| Return on Invested Capital (ROIC) | -171.42% | -509.00% | -59.35% | -122.13% | -2805.16% |
| Return on Tangible Assets | -1017.74% | -184210.53% | 0.00% | -656.61% | -123.49% |
| Earnings Yield | -4.51% | -7.06% | -2.98% | -4.92% | -7.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -25155.67 | 0.00 | 0.00 | 0.00 | -200084.33 |
| Capital Expenditure Coverage Ratio | -25155.67 | 0.00 | 0.00 | 0.00 | -200084.33 |
| Operating Cash Flow Coverage Ratio | -4.01 | -2.00 | -1.94 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2.18% | -1.14% | -1.49% | -12.77% | -33.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.26 | -14.17 | -33.52 | -20.34 | -13.55 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 62.73 | 92.48 | 23.57 | 12.18 | 341.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -45.85 | -87.87 | -67.07 | -7.83 | -3.00 |
| Price-to-Operating Cash Flow Ratio | -45.85 | -87.87 | -67.07 | -7.83 | -3.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.72 | -0.04 | 1.23 | 0.34 | 0.17 |
| Enterprise Value Multiple | -28.78 | -12.28 | -39.94 | -24.14 | 16.42 |
| Enterprise Value | 3.46M | 2.99M | 1.43M | 1.08M | 1.70M |
| EV to EBITDA | -28.78 | -12.28 | -39.94 | -24.14 | 16.42 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -45.90 | -88.37 | -67.58 | -7.77 | -2.83 |
| EV to Operating Cash Flow | -45.90 | -88.37 | -67.58 | -7.77 | -2.83 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.23 | 0.84 | 1.00 | 1.05 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.48 | 0.16 | 0.50 | 2.60 | -60.80 |
Currency in USD
